# The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.

> **NCT06823323** · NA · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 150 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (CRC)

## Interventions

- **DIETARY_SUPPLEMENT:** Lactobacillus johnsonii
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06823323
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06823323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06823323, "The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06823323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*